EUVIMEDEUVIMED entdecken
Crossref

A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma

Rohan R Katipally, Greeshma Rajeev-Kumar, Abhishek A Solanki, Fauzia Arif, Scott E Eggener, Abhinav Sidana, Russell Z Szmulewitz, Walter M Stadler, Randy F Sweis, Sean P Pitroda, Stanley L Liauw

International Journal of Radiation Oncology*Biology*Physics · 2026-05 · 125 (1) · 164-170

DOI: 10.1016/j.ijrobp.2025.05.059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-05. Verfasst von Rohan R Katipally und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Ilinois. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Radiosurgery, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Metastasis-directed therapy for oligometastatic renal cell carcinoma (RCC) with stereotactic body radiation therapy (SBRT) has been shown to improve progression-free survival (PFS) and delay time to systemic therapy. Here, we present long-term follow-up of a prospective trial. METHODS AND MATERIALS: Patients with oligometastatic or recurrent RCC (1-5 lesions, with no therapies in prior month) were enrolled on a pilot study (NCT02542202). SBRT was delivered to all sites (preferred regimen of 50 Gy in 5 fractions). The primary endpoint was the rate of grade 4+ adverse events, and secondary endpoints included local failure, distant progression, and PFS. Exploratory endpoints included time to subsequent systemic therapy and time to subsequent metastasis-directed therapy. RESULTS: Fifteen patients (all with resected primary tumors, 40% prior systemic therapy, 47% International Metastatic RCC (Renal Cell Carcinoma) Database Consortium intermediate risk) received SBRT to 23 lesions (median, 1; range, 1-4; median BED10 (Biologically Effective Dose, α/β=10) of 100 Gy; 43% lung, 35% abdomen, 17% bone, 4% head and neck). The trial was closed early due to slow accrual. At a median follow-up of 4.8 years, there were no grade 3+ adverse events (AEs) and no late grade 2+ AEs. Five (33%) patients experienced 7 acute grade 2 AEs. Two-year PFS was 46% (90% CI, 24%-65%). At 5 years, cumulative incidence of local failure was 6.7% (90% CI, 0.8%-22%), distant progression was 85% (90% CI, 60%-95%), subsequent systemic therapy was 54% (90% CI, 31%-73%), and subsequent metastasis-directed therapy was 52% (90% CI, 22%-76%). The median time to subsequent systemic therapy was 2.6 years. CONCLUSIONS: Multisite SBRT in oligometastatic RCC offers excellent local control with a low risk of severe late toxicity. This study supports an approach to treat limited metastatic disease with SBRT to delay additional systemic therapy. A subset of patients may benefit from additional, repeated ablative local interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellRadiosurgeryKidney NeoplasmsHumansMaleAgedMiddle AgedFemaleProspective StudiesAged, 80 and overPilot ProjectsProgression-Free SurvivalNeoplasm MetastasisFollow-Up StudiesAdultNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Ilinois.
  • Department of Radiation Oncology, Loyola University Medical Center, Maywood, Ilinois.
  • Department of Surgery, Section of Urology, University of Chicago, Chicago, Ilinois.
  • Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Ilinois.
  • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Ilinois. Electronic address: sliauw@uchicago.edu.

Zitieren

APA

Katipally, R. R., Rajeev-Kumar, G., Solanki, A. A., Arif, F., Eggener, S. E., Sidana, A., Szmulewitz, R. Z., Stadler, W. M., Sweis, R. F., Pitroda, S. P., & Liauw, S. L. (2026). A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 125(1), 164-170. https://doi.org/10.1016/j.ijrobp.2025.05.059

Vancouver

Katipally RR, Rajeev-Kumar G, Solanki AA, Arif F, Eggener SE, Sidana A, et al. A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2026;125(1):164-170. doi:10.1016/j.ijrobp.2025.05.059

BibTeX
@article{Katipally2026,
  author = {Katipally, Rohan R and Rajeev-Kumar, Greeshma and Solanki, Abhishek A and Arif, Fauzia and Eggener, Scott E and Sidana, Abhinav and Szmulewitz, Russell Z and Stadler, Walter M and Sweis, Randy F and Pitroda, Sean P and Liauw, Stanley L},
  title = {A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {125},
  number = {1},
  pages = {164--170},
  doi = {10.1016/j.ijrobp.2025.05.059}
}
Kostenlos starten →